TGFB1 and chronic kidney disease: Besides, in MAPK-agonist treatment group, the expression levels of MyHC, TGF-β, COL-1 were significantly increased compared with the si-CCN + CKD serum group, while a similar trend was not seen in the expression of ANP (Figures 8(e), 8(f), 8(g), 8(h), 8(i), and 8(j)).